Cost-effectiveness of intravascular ultrasound-guided percutaneous intervention in patients with acute coronary syndromes: a UK perspective.

IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Andrew S P Sharp, Tim Kinnaird, Nick Curzen, Ruba Ayyub, Jorge Emilio Alfonso, Mamas A Mamas, Henri Vanden Bavière
{"title":"Cost-effectiveness of intravascular ultrasound-guided percutaneous intervention in patients with acute coronary syndromes: a UK perspective.","authors":"Andrew S P Sharp, Tim Kinnaird, Nick Curzen, Ruba Ayyub, Jorge Emilio Alfonso, Mamas A Mamas, Henri Vanden Bavière","doi":"10.1093/ehjqcco/qcad073","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Use of intravascular ultrasound (IVUS) during percutaneous coronary intervention (PCI) is associated with improved clinical outcomes over angiography alone. Despite this, the adoption of IVUS in clinical practice remains low.</p><p><strong>Aims: </strong>To examine the cost-effectiveness of IVUS-guided PCI compared to angiography alone in patients with acute coronary syndromes (ACS).</p><p><strong>Methods and results: </strong>A 1-year decision tree and lifetime Markov model were constructed to compare the cost-effectiveness of IVUS-guided PCI to angiography alone for two hypothetical adult populations consisting of 1000 individuals: ST-elevation myocardial infarction (STEMI) and unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) patients undergoing drug-eluting stent (DES) implantation. The United Kingdom (UK) healthcare system perspective was applied using 2019/20 costs. All-cause death, myocardial infarction (MI), repeat PCI, lifetime costs, life expectancy, and quality-adjusted life-years (QALYs) were assessed. Over a lifetime horizon, IVUS-guided PCI was cost-effective compared to angiography alone in both populations, yielding an incremental cost-effectiveness ratio of £3649 and £5706 per-patient in STEMI and UA/NSTEMI patients, respectively.In the 1-year time horizon, the model suggested that IVUS was associated with reductions in mortality, MI, and repeat PCI by 51%, 33%, and 52% in STEMI and by 50%, 29%, and 57% in UA/NSTEMI patients, respectively. Sensitivity analyses demonstrated the robustness of the model with IVUS being 100% cost-effective at a willingness to pay threshold of £20 000 per QALY-gained.</p><p><strong>Conclusions: </strong>From a UK healthcare perspective, an IVUS-guided PCI strategy was highly cost-effective over angiography alone amongst ACS patients undergoing DES implantation due to the medium- and long-term reduction in repeat PCI, death, and MI.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":"677-688"},"PeriodicalIF":4.8000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcad073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Use of intravascular ultrasound (IVUS) during percutaneous coronary intervention (PCI) is associated with improved clinical outcomes over angiography alone. Despite this, the adoption of IVUS in clinical practice remains low.

Aims: To examine the cost-effectiveness of IVUS-guided PCI compared to angiography alone in patients with acute coronary syndromes (ACS).

Methods and results: A 1-year decision tree and lifetime Markov model were constructed to compare the cost-effectiveness of IVUS-guided PCI to angiography alone for two hypothetical adult populations consisting of 1000 individuals: ST-elevation myocardial infarction (STEMI) and unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) patients undergoing drug-eluting stent (DES) implantation. The United Kingdom (UK) healthcare system perspective was applied using 2019/20 costs. All-cause death, myocardial infarction (MI), repeat PCI, lifetime costs, life expectancy, and quality-adjusted life-years (QALYs) were assessed. Over a lifetime horizon, IVUS-guided PCI was cost-effective compared to angiography alone in both populations, yielding an incremental cost-effectiveness ratio of £3649 and £5706 per-patient in STEMI and UA/NSTEMI patients, respectively.In the 1-year time horizon, the model suggested that IVUS was associated with reductions in mortality, MI, and repeat PCI by 51%, 33%, and 52% in STEMI and by 50%, 29%, and 57% in UA/NSTEMI patients, respectively. Sensitivity analyses demonstrated the robustness of the model with IVUS being 100% cost-effective at a willingness to pay threshold of £20 000 per QALY-gained.

Conclusions: From a UK healthcare perspective, an IVUS-guided PCI strategy was highly cost-effective over angiography alone amongst ACS patients undergoing DES implantation due to the medium- and long-term reduction in repeat PCI, death, and MI.

血管内超声引导下经皮介入治疗急性冠状动脉综合征患者的成本效益:英国视角。
背景:与单纯血管造影术相比,在经皮冠状动脉介入治疗(PCI)过程中使用血管内超声(IVUS)可改善临床疗效。目的:研究急性冠状动脉综合征(ACS)患者在血管内超声引导下进行 PCI 与单纯血管造影术相比的成本效益:方法:我们构建了一个为期一年的决策树和终身马尔可夫模型,以比较两种假定的成人群体(由 1,000 人组成)在 IVUS 引导下行 PCI 与单纯血管造影术的成本效益:ST段抬高型心肌梗死(STEMI)和不稳定型心绞痛/非ST段抬高型心肌梗死(UA/NSTEMI)患者接受药物洗脱支架(DES)植入术。英国医疗保健系统采用2019/20年成本观点。对全因死亡、心肌梗死(MI)、重复PCI、终生成本、预期寿命和质量调整生命年(QALYs)进行了评估:结果表明:与单纯血管造影术相比,IVUS引导下PCI术在两种人群中的终生成本效益都很高,在STEMI和UA/NSTEMI患者中,每名患者的增量成本效益比分别为3649英镑和5706英镑。模型显示,在一年的时间跨度内,IVUS 可使 STEMI 患者的死亡率、心肌梗死率和重复 PCI 率分别降低 51%、33% 和 52%,使 UA/NSTEMI 患者的死亡率、心肌梗死率和重复 PCI 率分别降低 50%、29% 和 57%。敏感性分析表明了模型的稳健性,在每QALY收益20,000英镑的支付意愿(WTP)阈值下,IVUS的成本效益为100%:从英国医疗保健的角度来看,在接受DES植入术的ACS患者中,IVUS引导的PCI策略比单纯的血管造影更具成本效益,因为中长期内重复PCI、死亡和心肌梗死的发生率都有所下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.40
自引率
3.80%
发文量
76
期刊介绍: European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信